3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
8
Urinary Bladder Neoplasms
3
Neoplasms
2
Urothelial Bladder Cancer
1
Urologic Neoplasms
1
Urinary Bladder Diseases
1
Recurrence
1
Driving Under the Influence
1
Disease Progression
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
91
Blood Specimen Collection
44
Cyclophosphamide
37
Nivolumab
36
Bevacizumab
36
Standard of Care
32
Carboplatin
31
Surveys and Questionnaires
29
Paclitaxel
28
atezolizumab
25
Exercise
25
Pemetrexed
24
Gemcitabine
24
Cisplatin
23
Fluorouracil
22
Radiotherapy
20
Leucovorin
20
Dexamethasone
20
Oxaliplatin
19
Docetaxel
19
Rituximab
16
Irinotecan
16
Cetuximab
16
dostarlimab
15
Drug Therapy
15
Doxorubicin
15
Biopsy
15
130-nm albumin-bound paclitaxel
15
Prednisone
14
Ipilimumab
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms
×
Multiparametric Magnetic Resonance Imaging
×
1 year
×
Clear all
NCT04442724
2025-08-14
FMBRT
Cedars-Sinai Medical Center
Phase NA
Recruiting
60 enrolled
NCT07067749
2025-07-24
TEMPO-MIBC
University of Rome Tor Vergata
Phase 3
Recruiting
92 enrolled